Zydus Lifesciences rises on bagging license for iron deficiency drug

9 Sep 2022 , 10:15 AM

MonoFerric, iron isomaltoside 1000 solution for injection or infusion is a rapid single dose IV iron which reduces the number of infusions required to achieve iron correction safely. MonoFerric is used for the treatment of iron deficiency in adult patients, people suffering from chronic kidney disease, when oral iron drugs are ineffective or cannot be used or when there is a need for rapid iron delivery. Mono Ferric is available in over 30 countries, including US and Europe. Over 28 million doses have been administered since launch. Sharvil Patel, managing director of Zydus Lifesciences said, ?Iron deficiency is a severe healthcare challenge and also impacts the quality of life more so in chronic kidney disease patients. With this introduction, we bring a novel solution to these patients and with our strong lastmile delivery, we will enable access to this critical therapy.? Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit fell 11.7% to Rs 518.3 crore on a 1.8% increase in total income from operations to Rs 4,072.7 crore in Q1 FY23 over Q1 FY22. Powered by Capital Market – Live News